The Latest Breaking News from Amphastar Pharmaceuticals

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

FDA approved Rextovy, a new OTC naloxone nasal spray, on June 16, 2026. Here's what changed, what it costs, and what fentanyl users' families should know.

Medical Daily · Jul 9

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China b

MarketBeat · Jun 4

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference. Bill Peters, chief financial officer of Amphastar

MarketBeat · May 14

Earnings Preview For Amphastar Pharmaceuticals

Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Amphastar Pharmaceuticals will report an earnings per share (EPS) of $0.37.

Benzinga · Mar 9, 2022